Founded in 2016, CoreMap is taking aim at atrial fibrillation with its technology designed to map complex arrhythmias inside the heart. Sarah Kalil is the company’s CEO and her partner is the clinical electrophysiologist who invented CoreMap’s technology.
Through the IGNITE program, Kalil had the chance to present about CoreMap at DeviceTalks Boston 2019.
“It really helped us refine our pitch. IGNITE worked with us to make sure the pitch was polished and on target. We had the opportunity to be in front of a room full of people, which the more you do it, the better you get. So those experiences, the network and the exposure are all impactful for my company,” she said.
“To date all of our testing has been done in a preclinical model. We just submitted to an IRB to do our first-in-human testing and that puts us that much closer to solving a very large problem for a very large patient population,” Kalil added. “About 32 million people have atrial fibrillation and because an electrophysiologist can’t see the arrhythmia in adequate resolution, they can’t treat it with available therapies. So we unlock that patient population to new therapeutic options. I’m really excited about getting that major milestone closer to being in the clinic as a solution for this patient population.”